A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional
28
News and Trends
News and Trends
SEPTEMBER 2011
THORNE RESEARCH LAUNCHES THORNE BARIATRIC, A NUTRITIONAL PRODUCT LINE FOR BARIATRIC SURGERY PATIENTS
DOVER, Idaho—Thorne Research, Inc., a dietary supplement manufacturer specializing in providing science- based, pure, hypoallergenic nutritional supplements, announced that it is launching a line of dietary supplements, Thorne Bariatric, for individuals who will undergo bariatric surgery, as well as for individuals who have had bariatric surgery and need nutritional
support to help maintain weight loss and adequate hydration. Thorne Research's science-based formulas will be marketed both to physician groups and to hospitals specializing in the moderately obese and severely obese patient populations, many of whom need nutritional support both before and after bariatric surgery. Thorne Bariatric nutritional product line for bariatric patients is formulated with natural sweeteners and flavorings. The entire line is aspartame- and sucralose-free. In addition, Thorne Bariatric dietary supplement product line includes
ImmunoLin® , which enhances
gastrointestinal and immune health. ImmunoLin®
system supplement.
"Nutrient deficiencies, which are common after weight loss surgery, can lead to side effects such as hair loss, impaired immunity, anemia, delayed wound healing, and even neuropathy. These complications can be minimized with vitamin and mineral supplementation in combination with nutritional laboratory analyses. But supplementation should be in a form that enhances bioavailability and absorption. Thorne Bariatric provides pure, highly absorbed nutrients and will be an important component in improving the quality of life of my bariatric patients," said Ninh T. Nguyen, MD, a board- certified gastrointestinal surgeon and specialist in laparoscopic bariatric surgery.
The initial Thorne Bariatric product line includes a powdered meal replacement formula, a multiple vitamin-mineral supplement, an electrolyte replacement formula, and several other supportive nutrient formulas that will assist bariatric surgery patients in achieving their new health goals. Alan Miller, ND, Thorne Research's Director of Medical Education and Research, stated that ImmunoLin, a proprietary ingredient, has the potential for tremendous growth because of the recent United States Food and Drug Administration (FDA) approval of adjustable gastric-banding surgery with Lap-Band®
(Allergan, Inc.,
Irvine, California) for patients with obesity with a body mass index (BMI) of at least 40kg/m2 at least 30kg/m2
or BMI of with one or more
obesity-related comorbid conditions.
Thorne Research also plans on complementing the Thorne Bariatric line by offering both practitioners and patients alike educational materials on patient compliance, exercise, and nutrition to help maximize the dietetic and weight maintenance benefits of the company's products.
For more information on Thorne Research, please visit www.thorne.com. See their ad on page 21.
is a fast-acting immune
BIORESTORATIVE THERAPIES SIGNS LICENSE AGREEMENT WITH UNIVERSITY OF UTAH TO OBTAIN ADIPOSE (FAT) TISSUE FOR ITS THERMOSTEM PROGRAM TO TREAT OBESITY AND METABOLIC DISORDERS JUPITER, Florida (PR Newswire)—BioRestorative Therapies (BRT), Inc. announced that it has entered into a Tangible Property License Agreement with the University of Utah. The two- year license agreement enables BioRestorative Therapies to obtain adipose (fat) tissue that will be used for research purposes to develop and commercialize its ThermoStem Program, which is an adult derived stem cell-based program to treat metabolic and obesity related disorders, using the thermogenic or heat producing properties of brown fat. The ThermoStem Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders.
The agreement marks the beginning of a strategic
collaboration between BRT and the University of Utah, an institution recognized as a leader in translational stem cell-based therapies. This relationship offers BRT an opportunity to procure adipose tissues from donors (tissue and cells that are usually difficult to obtain) to be used for BRT's cellular research and characterization studies. Dr. Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah and a member of the BRT Scientific Advisory Board, said, "Obesity is now the leading cause of preventable death and BRT's ThermoStem Program is a novel cell-based approach to treat this disorder."
For more information, please visit www.stemcellassurance.com.
Bariatric Times • September 2011